查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1524225

女性性功能障碍治疗市场 - 依药物（氟班色林、布雷默诺肽、欧培米芬、雌激素治疗）、疾病（性交困难、HSDD）、给药途径（口服、肠胃外、局部）、配销通路- 全球预测（2024 - 2032）

Female Sexual Dysfunction Treatment Market - By Drug (Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy), Disease (Dyspareunia, HSDD), Route of Administration (Oral, Parenteral, Topical), Distribution Channel - Global Forecast (2024 - 2032)
出版日期: | 出版商: Global Market Insights Inc. | 英文 210 Pages | 商品交期: 2-3个工作天内

价格
简介目录

在针对女性性功能障碍各个方面的治疗方法的进步以及人们对性健康问题的认识不断提高和消除污名化的推动下，全球女性性功能障碍治疗市场从2024 年到2032 年将实现10% 的复合年增长率。

随着性慾减退症 HSDD 等疾病的新疗法获得批准以及接受度和教育工作的扩大，越来越多的女性正在寻求有效的解决方案。这一趋势正在促进对个人化和有效疗法的需求不断增长，以增强获得全面护理的机会，并有助于解决全球多样化的性健康需求。例如，2023 年 12 月，Sha Wellness Clinic 引入了性健康部门，作为其预防和健康老龄医学计划的一部分，重点关注全面健康。

女性性功能障碍治疗产业根据药物、疾病、给药途径、配销通路和地区进行分类。

从药物来看，欧司哌米芬细分市场将在 2032 年实现强劲增长，因为它能有效解决更年期女性的阴道干燥和性交疼痛等症状。随着其被批准用于荷尔蒙受体阳性乳癌患者和非雌激素作用机制，欧司哌米芬提供了一种可行的治疗选择。随着医疗保健提供者寻求安全有效的性健康问题治疗方法，欧司哌米芬将提供功效和安全性，使其成为不断发展的女性性功能障碍治疗领域的领先选择。

就疾病而言，HSDD细分市场在2024年至2032年间将出现值得注意的复合年增长率。随着人们对氟班色林（专门批准用于 HSDD）等治疗方案的认识不断提高和进步，人们越来越关註解决这一普遍问题。医疗保健提供者对改善性健康和生活品质的高度重视将有利于该细分市场的成长。

由于医疗保健意识的提高和对个人化治疗的需求不断增长，到 2032 年，亚太地区女性性功能障碍治疗市场将占据重要份额。随着医疗基础设施和研究计画的不断扩大，该地区的多元化人口正在为推进治疗方案做出重大贡献。随着各国政府优先考虑女性健康以及不断发展的监管框架，亚太地区将脱颖而出，成为推动产业成长的核心贡献者。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
    • 提高对女性性健康议题的认识
    • 越来越关注女性健康
    • 不断增加的研发活动
    • 医疗技术不断进步
    • 产业陷阱与挑战
    • 与女性性健康相关的社会耻辱和禁忌
    • 治疗费用高
  • 成长潜力分析
  • 监管环境
  • 技术景观
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司市占率分析
  • 竞争定位矩阵
  • 战略展望矩阵

第 5 章：市场估计与预测：按药品分类，2021 - 2032 年

  • 主要趋势
  • 氟班色林
  • 布雷默诺胜肽
  • 欧司哌米芬
  • 雌激素治疗
  • 其他药品

第 6 章：市场估计与预测：按疾病分类，2021 - 2032 年

  • 主要趋势
  • 性交困难
  • 性慾减退症（HSDD）
  • 其他疾病

第 7 章：市场估计与预测：按管理途径，2021 - 2032 年

  • 主要趋势
  • 口服
  • 注射用
  • 专题

第 8 章：市场估计与预测：按配销通路划分，2021 - 2032 年

  • 主要趋势
  • 医院药房
  • 零售药局
  • 网路药局

第 9 章：市场估计与预测：按地区，2021 - 2032

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 拉丁美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 南非
    • 阿联酋
    • 中东和非洲其他地区

第 10 章：公司简介

  • Apricus Biosciences, Inc.
  • Cipla Limited
  • Freya Pharma Solutions
  • GSK plc
  • Lawley Pharmaceuticals Pty Ltd.
  • Merck & Co., Inc.
  • Millicent Pharma Limited
  • Novo Nordisk
  • Pfizer, Inc.
  • Sprout Pharmaceuticals, Inc
简介目录
Product Code: 9138

Global Female Sexual Dysfunction Treatment Market will witness 10% CAGR from 2024 to 2032, fueled by advancements in therapeutics targeting various aspects of female sexual dysfunction, coupled with increasing awareness and destigmatization of sexual health issues.

As new treatments for conditions like hypoactive sexual desire disorder HSDD are gaining approval as well as acceptance and educational efforts are expanding, more women are seeking effective solutions. This trend is fostering a growing demand for personalized and effective therapies for enhancing access to comprehensive care and contributing to the evolution towards addressing diverse sexual health needs globally. For instance, in December 2023, Sha Wellness Clinic introduced a Sexual Health Unit as part of its Preventive and Healthy Ageing Medicine program for focusing on comprehensive wellness.

The female sexual dysfunction treatment industry is classified based on drug, disease, route of administration, distribution channel, and region.

By drug, the ospemifene segment will witness robust growth through 2032 due to its effectiveness in addressing symptoms like vaginal dryness and dyspareunia in menopausal women. With its approval for use in hormone receptor-positive breast cancer patients and non-estrogenic mechanism of action, ospemifene offers a viable therapeutic option. As healthcare providers seek safe and effective treatments for sexual health issues, ospemifene will render efficacy and safety, making it a leading choice in the evolving landscape of female sexual dysfunction treatments.

In terms of disease, the HSDD segment will observe a noteworthy CAGR between 2024 and 2032. As the most common form of female sexual dysfunction, HSDD affects libido and intimacy. With increasing awareness and advancements in treatment options like flibanserin, approved specifically for HSDD, there is a growing focus on addressing this prevalent issue. The strong emphasis of healthcare providers on improving sexual wellness and quality of life will favor the segment growth.

Asia Pacific female sexual dysfunction treatment market will hold significant share by 2032, attributed to increasing healthcare awareness and the rising demand for personalized therapies. With expanding healthcare infrastructure and research initiatives, the diverse population of the region is contributing significantly to advancing treatment options. With governments prioritizing women health and the evolving regulatory frameworks, Asia Pacific will stand out as a central contributor to shaping the industry growth.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
    • 3.2.2 Increasing awareness regarding female sexual health issues
    • 3.2.3 Growing focus towards women's health
    • 3.2.4 Rising research & development activities
    • 3.2.5 Increasing advancements in medical technology
    • 3.2.6 Industry pitfalls & challenges
    • 3.2.7 Societal stigma and taboos associated with female sexual health
    • 3.2.8 High treatment costs
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Technological landscape
  • 3.6 Porter's analysis
  • 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Competitive positioning matrix
  • 4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Drug, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Flibanserin
  • 5.3 Bremelanotide
  • 5.4 Ospemifene
  • 5.5 Estrogen therapy
  • 5.6 Other drugs

Chapter 6 Market Estimates and Forecast, By Disease, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Dyspareunia
  • 6.3 Hypoactive sexual desire disorder (HSDD)
  • 6.4 Other diseases

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Oral
  • 7.3 Parenteral
  • 7.4 Topical

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospital pharmacies
  • 8.3 Retail pharmacies
  • 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
    • 9.4.6 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
    • 9.5.4 Rest of Latin America
  • 9.6 Middle East and Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 South Africa
    • 9.6.3 UAE
    • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

  • 10.1 Apricus Biosciences, Inc.
  • 10.2 Cipla Limited
  • 10.3 Freya Pharma Solutions
  • 10.4 GSK plc
  • 10.5 Lawley Pharmaceuticals Pty Ltd.
  • 10.6 Merck & Co., Inc.
  • 10.7 Millicent Pharma Limited
  • 10.8 Novo Nordisk
  • 10.9 Pfizer, Inc.
  • 10.10 Sprout Pharmaceuticals, Inc